stockrowInsmed, Inc.
INSM Healthcare Biotechnology
Insmed, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $606.4 million, up 66.7% from fiscal 2024.
- Revenue
- +268.4%
- EPS
- +73.8%
- Free cash flow
- +81.1%
- Total debt
- +0.27%
Quarter to September 2026, against a year earlier
Follow INSM
Alert me
Insmed, Inc. (INSM) Revenue
Insmed, Inc.'s revenue for fiscal 2025 was $606.4M, up 66.7% from $363.7M in fiscal 2024. Over the twelve months to 30 September 2026 it was $1.5B. Over the past ten years it has ranged from $9.8M (fiscal 2018) to $606.4M (fiscal 2025) — the current reading is the highest in ten years. Revenue has risen for 7 consecutive fiscal years. Insmed, Inc. ranks 17th of 390 Biotechnology companies by revenue.
Revenue, annual
Embed this chart
Annual newest first
| Period | Revenue | Change |
|---|---|---|
| FY2025 | $606.4M | 66.73% |
| FY2024 | $363.7M | 19.17% |
| FY2023 | $305.2M | 24.39% |
| FY2022 | $245.4M | 30.19% |
| FY2021 | $188.5M | 14.63% |
| FY2020 | $164.4M | 20.48% |
| FY2019 | $136.5M | 1,287.56% |
| FY2018 | $9.8M | — |
Quarterly newest first
| Period | Revenue | Change |
|---|---|---|
| Sep 2026 | $524.4M | 23.25% |
| Jun 2026 | $425.5M | 39.06% |
| Mar 2026 | $306.0M | 15.96% |
| Dec 2025 | $263.8M | 85.36% |
| 27 more quarters | Free account |
Against its own ten years
Revenue against peers
| Company | Revenue |
|---|---|
| INCY Incyte Corporation compare | $6.0B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $5.0B |
| GMAB Genmab A/S Sponsored ADR compare | $4.1B |
| BNTX BioNTech SE Sponsored ADR compare | $2.7B |
| EXEL Exelixis, Inc. compare | $2.5B |
| INSM Insmed, Inc. | $1.5B |
| ASND Ascendis Pharma A/S compare | $1.2B |
| BBIO BridgeBio Pharma, Inc. compare | $945.5M |
| ROIV Roivant Sciences Ltd. compare | $7.5M |
What Revenue is
Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.
Reported line item
More on INSM
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement